Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients

Withdrawn before enrolling · Not applicable

Conditions studied: Glioblastoma Multiforme, Recurrent Glioma

In brief

This pilot study looks at how certain diet changes affect the body in patients with recurrent brain tumors (glioma) who are planning to have standard treatment like radiation or surgery. Up to 30 patients will be randomly assigned to either a regular diet or a special diet that limits two nutrients (cysteine and methionine) for 2, 4, or 7 days before their treatment. Patients will be monitored for side effects using blood tests and questionnaires, and patients will keep a diary to track how well they follow the diet. Blood and urine samples will be used to see how the diet affects the body. Tumor samples (from surgery) will help researchers study how the cancer cells behave, and stool samples will be used to look at gut bacteria. This is a randomized, blinded interventional pilot study to measure glutathione metabolite levels with a cysteine/methionine deprivation (CMD) diet in glioma patients. A menu of pre-prepared meals will be provided to subjects that consist of either a control diet or a CMD diet. The CMD diet will be implemented simultaneously in 2 cohorts of participants with recurrent glioma. The primary objective will be to measure the metabolic state of glioblastome multiforme tumor cells through dietary restriction of the sulfur-containing amino acids (SAA), cysteine/cystine and methionine. Patient from cohort A can later be included in Cohort B if applicable. Patients will be followed for progression free survival and overall survival for up to 1 year, or until they discontinue or are removed from the study for exploratory endpoints.

Key facts

Study ID

NCT07553520

Run by

UNC Lineberger Comprehensive Cancer Center

People needed

0

Starts

2026-05-01

Expected to finish

2028-07-01

Last updated by the study team

2026-04-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
• Subjects is willing and able to comply with study procedures based on the judgement of the investigator.
• Age ≥ 18 years at the time of consent.
• Karnofsky Performance Status of ≥ 60 assessed at diagnosis

You may not qualify if…

• Active infection requiring systemic therapy.
• Any active disease that may be associated with unacceptable anesthetic/operative risk.
• Pregnant or breastfeeding
• Subjects with prior brain metastasis.
• Transfusion within 7 days of diet initiation

Where it is running

• University of North Carolina at Chapel Hill, Department of Radiation Oncology — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.